| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3292952 | Gastroenterology | 2012 | 13 Pages |
Abstract
Administration of antigen-specific Tregs to patients with refractory CD (CATS1) was well tolerated and had dose-related efficacy. The ovalbumin-specific immune response correlated with clinical response, supporting immune-suppressive mechanisms of ova-Tregs. The consistency of results among different assessment methods supports the efficacy of ova-Tregs; this immune therapy approach warrants further clinical and mechanistic studies in refractory CD. Eudract, Number: 2006-004712-44.
Keywords
OVALOCFCDAISAETregPPDIBDQPBMCT-regulatory cellTNFOvalbuminimmunotherapyinterleukinITTInflammatory bowel diseasetetanus toxoidPeripheral blood mononuclear celladverse eventSerious adverse eventtumor necrosis factorintention-to-treatlast observation carried forwardpurified protein derivativeInflammatory Bowel Disease QuestionnaireC-reactive proteinCRPClinical trial
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Pierre Desreumaux, Arnaud Foussat, Matthieu Allez, Laurent Beaugerie, Xavier Hébuterne, Yoram Bouhnik, Maria Nachury, Valérie Brun, Hervé Bastian, Nathalie Belmonte, Michel Ticchioni, Agnès Duchange, Patricia Morel-Mandrino, Virginie Neveu,